Pasithea Therapeutics Corp. · NASDAQ:KTTA
Pasithea Therapeutics — IPO Roadshow (August 2021)
17 slides from Pasithea Therapeutics's IPO roadshow presentation, Aug 6, 2021
Slide 1: Corporate Presentation
COPYRIGHT © 2021 PASITHEA Corporate Presentation 1
Slide 2: Forward-Looking Statements
COPYRIGHT © 2021 PASITHEA FORWARD - LOOKING STATEMENTS This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be an y sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior
Slide 3: Offering Summary
COPYRIGHT © 2021 PASITHEA OFFERING SUMMARY 3 Issuer: Pasithea Therapeutics Corp. Proposed Exchange / Tickers: Nasdaq Capital Market / KTTA, KTTAW Offering Type: Underwritten Initial Public Offering Securities Issued: Common Stock and Warrants Gross Offering Proceeds (including Over - Allotment): Up
Slide 4: Introduction to Pasithea Therapeutics
COPYRIGHT © 2021 PASITHEA INTRODUCTION TO PASITHEA THERAPEUTICS 4 Pasithea Therapeutics is a biotech company at the forefront of neuroscience research Drug development: Focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders Clinic partnership
Slide 5: Investment Highlights
COPYRIGHT © 2021 PASITHEA INVESTMENT HIGHLIGHTS 5 Large Addressable Market With Few Options for Adequate Help Today Capital - Light Infrastructure Diversified Revenue Stream with Significant Revenue and EBITDA Growth Potential Seasoned Leadership Team with Expertise in Neuroscience & Psychopharmacol
Slide 6: Large and Growing Addressable Market
COPYRIGHT © 2021 PASITHEA LARGE AND GROWING ADDRESSABLE MARKET 6 64.6 Million Estimated number of adults suffering from some type of mental health issue in the U.S. 1 US$16.1 Trillion Lost between 2010 and 2030 due to mental health conditions 2 US$19.2 Billion Estimated size of anxiety and depressio
Slide 7: The Stark Reality of the Global Treatment Gap
COPYRIGHT © 2021 PASITHEA THE STARK REALITY OF THE GLOBAL TREATMENT GAP 7 Overall Dropout Only a minority of participants with MDD received minimally adequate treatment HIGH - INCOME LOW - INCOME 1 in 5 people 3 1 in 27 people 3 COUNTRIES TREATMENT RECEIVED OVERALL DROP OUT RATE: 31.7% 4 » Estimates
Slide 8: Even Those Who Do Get Treatment Face Challenges
COPYRIGHT © 2021 PASITHEA EVEN THOSE WHO DO GET TREATMENT FACE CHALLENGES 8 Current treatments for psychiatric disorders are inadequate. Conventional medicines have low success rates in long - term treatment, and New types of drugs are limited by working through the same mechanisms . DIZZINESS HEADA
Slide 9: Primary Focus: Developing New Molecular Entities and/or Novel Biologic Drugs
COPYRIGHT © 2021 PASITHEA PRIMARY FOCUS: DEVELOPING NEW MOLECULAR ENTITIES AND/OR NOVEL BIOLOGIC DRUGS 9 Drugs targeting novel mechanism of action Next 24 MONTHS Phase 1 Phase 2 Phase 3 Develop 3 lead compounds focused on psychiatric and neurological disorders Focuses on: • Targets that can be devel
Slide 10: Secondary Focus: Clinic Partnerships to Deliver Ketamine Treatments
COPYRIGHT © 2021 PASITHEA SECONDARY FOCUS: CLINIC PARTNERSHIPS TO DELIVER KETAMINE TREATMENTS 10 Will provide intravenous infusions of ketamine to treat mental health disorders, such as Treatment - Resistant Depression (TRD) and Post - Traumatic Stress Disorder (PTSD) Will give immediate access to p
Slide 11: Clinic Partnerships to Deliver Ketamine Treatments – United Kingdom
COPYRIGHT © 2021 PASITHEA SECONDARY FOCUS: CLINIC PARTNERSHIPS TO DELIVER KETAMINE TREATMENTS – UNITED KINGDOM 11 Operations in the UK will involve providing business support services to registered healthcare providers who will assess pati ent s and administer IV infusion of ketamine, if appropriate
Slide 12: UK Clinic Partnership
COPYRIGHT © 2021 PASITHEA UK CLINIC PARTNERSHIP 12 • Capital - light partnership with Zen Healthcare • Zen Healthcare has two locations in London: Knightsbridge and Baker Street • Provides immediate exposure in the UK • Existing management structure and qualified GPs, pharmacists, therapists and psy
Slide 13: Clinic Partnerships to Deliver Ketamine Treatments – United States
COPYRIGHT © 2021 PASITHEA SECONDARY FOCUS: CLINIC PARTNERSHIPS TO DELIVER KETAMINE TREATMENTS – UNITED STATES Operations in the US will involve providing business support services to registered healthcare providers who will assess pati ent s and administer IV infusion of ketamine, if appropriate. Pa
Slide 14: US Partnership
COPYRIGHT © 2021 PASITHEA US PARTNERSHIP 14 NYC Base Deal Terms: • Plan to market and roll out nationwide 22.5K Pasithea pays IV Doc a fixed monthly fee of $22,500 The IV Doc 50,000 Patients 7 Years of operating • Partnered with The IV Doc, a leading provider of administrative and support services t
Slide 15: Pasithea's Competitive Landscape in the Mental Health Sector
COPYRIGHT © 2021 PASITHEA PASITHEA’S COMPETITIVE LANDSCAPE IN THE MENTAL HEALTH SECTOR 15
Slide 16: Improving Mental Health Treatments and Driving Shareholder Value
COPYRIGHT © 2021 PASITHEA IMPROVING MENTAL HEALTH TREATMENTS AND DRIVING SHAREHOLDER VALUE 16 Seasoned Leadership Team with Expertise in Neuroscience & Psychopharmacology Diversified Revenue Stream with Significant Revenue and EBITDA Growth Potential Capital - Light Infrastructure Large Addressable
Slide 17: Contact
COPYRIGHT © 2021 PASITHEA 17 www.pasitheaclinics.com Contact: Ed Tsuker Head of Capital Markets EF Hutton etsuker@efhuttongroup.com